Semler to Report Fourth Quarter and Year End 2022 Financial Results and Host Conference Call on March 21, 2023

Rhea-AI Summary

S Santa Clara, Calif., March 10, 2023 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ: SMLR) announced it will report its financial results for Q4 and full-year 2022 on March 21, 2023, after U.S. markets close. CEO Doug Murphy-Chutorian will lead a conference call at 4:30 PM ET, alongside key executives from finance, marketing, and communications. Participants can pre-register for the call or dial in directly. Semler's mission focuses on improving clinical effectiveness through innovative healthcare solutions, including the FDA-cleared QuantaFlo® test for cardiovascular diseases.

Positive

• Scheduled Q4 and full-year 2022 financial results could indicate business growth.
• CEO Doug Murphy-Chutorian leading the call may boost investor confidence.

Negative

• None.

News Market Reaction – SMLR

-3.95%

-3.95% Session move

In the trading session that priced this news, SMLR declined 3.95%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SANTA CLARA, Calif., March 10, 2023 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2022, after the close of U.S. financial markets on Tuesday, March 21, 2023. Doug Murphy-Chutorian, M.D., chief executive officer of Semler Scientific, will host a conference call at 4:30 pm ET the same day. Andrew Weinstein, senior vice president, finance and accounting, Dennis Rosenberg, chief marketing officer, and Renae Cormier, head of corporate communications and business strategy, will join him on the call.

We encourage participants to pre-register for the conference call using the following link: https://dpregister.com/sreg/10174345/f57dcc93c7. Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time.

Those without internet access or unable to pre-register may dial in by calling:
Domestic callers: 866-777-2509
International callers: 412-317-5413

Please specify to the operator that you would like to join the "Semler Scientific Call." The conference call will be archived on Semler Scientific's website at www.semlerscientific.com.

About Semler Scientific, Inc.:
Semler Scientific, Inc. is a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers. Semler Scientific's mission is to develop, manufacture and market innovative products and services that assist its customers in evaluating and treating chronic diseases. Semler Scientific's patented and U.S. Food and Drug Administration (FDA) cleared product, QuantaFlo®, is a rapid point-of-care test that measures arterial blood flow in the extremities to aid in the diagnosis of cardiovascular diseases, such as peripheral arterial disease (PAD). QuantaFlo® is used by Semler Scientific's customers to evaluate their patients more comprehensively for risk of mortality and major adverse cardiovascular events (MACE), associated with a positive QuantaFlo® test. Semler Scientific has an agreement with Mellitus Health to exclusively market and distribute Insulin Insights™, an FDA cleared software product that recommends optimal insulin dosing for diabetic patients in the United States, including Puerto Rico, except for selected accounts, and has made an investment in this private software company. Semler Scientific has also invested in privately held Monarch Medical Technologies, whose product, EndoTool®, is used for glycemic management in inpatient settings and in SynapsDX, whose product, Discern™, is a test for early Alzheimer's disease. Semler Scientific continues to develop additional complementary innovative products in-house and seeks out other arrangements for additional products and services that it believes will bring value to its customers and to the company. Semler Scientific believes its current products and services, and any future products or services that it may offer, positions it to provide valuable information to its customer base, which in turn permits them to better guide patient care. Additional information about Semler Scientific can be found at www.semlerscientific.com.

###

CONTACT:
Susan A. Noonan
S.A. Noonan Communications
susan@sanoonan.com
917 513 5303

View original content:https://www.prnewswire.com/news-releases/semler-to-report-fourth-quarter-and-year-end-2022-financial-results-and-host-conference-call-on-march-21-2023-301768669.html

SOURCE Semler Scientific, Inc.

FAQ

When will Semler Scientific report its Q4 and full-year 2022 financial results?

Semler Scientific will report its financial results on March 21, 2023.

What time is the Semler Scientific conference call for the financial results?

The conference call will be held at 4:30 PM ET on March 21, 2023.

How can I participate in the Semler Scientific conference call?

Participants can pre-register for the call or dial 866-777-2509 (domestic) or 412-317-5413 (international).

What is Semler Scientific known for?

Semler Scientific provides technology solutions like the QuantaFlo® test for improving clinical effectiveness in healthcare.